Salmonella is a major issue for all stakeholders in the food chain. Its control represents
a significant market for animal health companies that manufacture antimicrobials,
vaccines and diagnostic tools - $423 million of Salmonella control products were
sold in 2002, and this figure is forecast to rise to $669 million by 2007. The
largest growth area will be vaccines, sales of which should see an eight-fold
increase over the next five years.
Salmonella: Market opportunities for the animal health industry analyses all aspects of this dynamic market, which is being driven by new product
development and increasingly stringent legislation.
The report answers all your questions including:
New EU legislation will force governments and producers to reduce significantly
or eliminate Salmonella incidence. What effects will these changes have on commercial
livestock production, the food chain and the market for Salmonella control products?
In May 2001, Merial announced a significant new R&D collaboration with the
UK biotechnology company, Microscience. What form of Salmonella vaccines are under
development and what technology does Microscience bring to the table?
Which species and regions account for the bulk of the world market for Salmonella
vaccines, and where will growth be concentrated over the next five years?
Who is at the cutting edge of Salmonella vaccine R&D, and which companies
have used gene modification to develop new products?
How effective are probiotics and prebiotics in the control of Salmonella, and
who are the leading manufacturers?
Who is exclusively marketing Megan's live Salmonella vaccines in the US, and
what products does Megan have in their R&D pipeline?
Chapter 1 Introduction
Chapter 2 Global pathogen incidence
Chapter 3 Regulations to control salmonella
Chapter 4 Salmonella diagnosis
Chapter 5 Methods of control
Chapter 6 The world market for salmonella products
Chapter 7 Company profiles
Salmonellosis is a serious zoonotic disease responsible for foodborne infections
that are frequently under-reported. The commonest serotypes found in humans are
also isolated from animals and birds. The trend towards increased food processing
and sophistication of the food-distribution system has led to the disease becoming
more prevalent, with the highest levels of infection occurring after periods of
high seasonal temperatures. The appearance of strains that show multiresistance
to a broad range of antimicrobials has led to fears of cross-over to human infections,
prohibiting successful treatment of bacteraemic/septicaemic patients. Genuine
public health concerns have resulted in the imposition of legislation in many
countries comprising monitoring and control measures to reduce or eliminate the
infection from farms. This offers the animal health industry the opportunity to
capitalise upon a potentially rewarding market sector, which is currently under-exploited,
in the interest of improving food quality standards and protecting public health.
The market consists of three major segments: antimicrobials (which look set to
decline slowly from a current level of around $76 million); diagnostics (which
represent a huge market value of approximately $324 million, due to the constant
monitoring of food produce for bacterial contamination together with on-farm surveying
of bacterial levels); and vaccines (which at present probably represent no more
than approximately $23 million, but which have the potential to grow rapidly to
approximately $178 million over the next five years). Forecasts of the potential
market value place the sector at approximately $669 million by 2008. Key market
drivers include political protection of export markets and the ability to stop
imports of potentially contaminated foodstuffs. This report summarises the current
epidemiological position and available products for the control of Salmonella.
Different control measures are discussed and companies active in the sector are
profiled. The report provides a concise overview of the complicated regulatory
environment and identifies the major products currently available.
